Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
about
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineCriteria for drugs used in pre-exposure prophylaxis trials against HIV infectionA fossil record of zidovudine resistance in transmitted isolates of HIV-1HIV-1 drug resistance and resistance testing.In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitroWorldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsPhenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.Population-based monitoring of HIV drug resistance in Namibia with early warning indicators.Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureSequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.The use of preexposure treatments for HIV prophylaxisThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.HIV antiretroviral resistance mutations among antiretroviral treatment-naive and -experienced patients in South Korea.Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failureViremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South AfricaHIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.2014 Update of the drug resistance mutations in HIV-1International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptaseDifferential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.Drug Resistance-Associated Mutations in Antiretroviral Treatment-Experienced Patients in Kuwait.
P2860
Q28343476-9C29A16E-F616-4CAC-8426-472813CB8D7FQ28362780-8DD20466-C751-486E-9757-6EE152E4AB65Q28379499-A951E635-A308-4CBD-8825-B7FD534D11CCQ28469067-27C74B9B-9386-4212-A2D4-2F50DBE5E997Q28775685-0CA58913-A7D7-4AF4-A5E5-573A3763510BQ30245693-D055CB5B-0778-41E9-8D9E-218ED9EC6972Q33724206-9985C168-6BFC-4BC6-84EA-E2DBA8DCEB69Q33906239-AC458923-DBDD-4031-BBAD-915BBF0E6965Q33938098-FE109C88-362B-4A10-85A5-75730C8C2CB3Q33961507-967B24EA-87DD-466E-8D37-7002DEFA413FQ33975889-D3CF6082-A754-4481-BC90-612DC459ED49Q34251987-D3995461-CCFF-426B-94C2-1E525ACA14BEQ34283361-B25DE778-1C43-4ED2-8966-A778D0DD2620Q34339657-ECA69D40-A4DE-4183-9085-5B0A2CF2255EQ34414078-4D766CC3-5577-48F0-9F18-376DA500F2D5Q34717892-F6C1D1A7-A46E-4171-9C9D-2B8B0AE6A0B9Q34803017-7C97A126-0BF5-422F-B6AB-093C6CFAF493Q35636514-191934B6-27BF-41A5-885A-666F246E11FFQ35698801-5A8EEC3D-B883-4DCA-A21E-CFADB6D2BA64Q35752812-DFDAA1A2-3459-4072-9AF4-64C8794D0358Q35760180-5BBE3438-0231-4D4B-97CF-D20269F1111EQ37018369-413464A1-3D10-4EEC-9D89-7C7495D12ACDQ37359155-3363F9E0-786E-4958-A4C0-FCA044EC4D2CQ37417912-4EEB8B2E-41A0-4A5C-87FE-099BF22C8E41Q37461877-3D3F2783-A96D-419C-9499-B5ADEA95EA06Q38375479-45712E5E-F675-41F6-A9CA-EEEBF1D18E73Q39498339-5DB50EA1-A668-4641-8205-F08A3D3911A0Q39895796-02A1FC96-A986-423C-8898-4F0E71278605Q40291316-78F764FB-CDD4-48AE-8B70-026503F10859Q40706086-7718417E-2C93-49AB-B022-70CC0DCD5A20Q41912300-261BF3E0-BB0B-4833-B372-8533E4D17C74Q43105557-66169672-C473-462F-A88C-D332EA0D9422Q52374199-F404F00A-C2B2-4F56-9648-DCF240A6D67BQ52673760-7CA7C162-3834-4105-9A85-F225410C3135
P2860
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Drug resistance and virologic ...... previously untreated patients.
@en
Drug resistance and virologic ...... previously untreated patients.
@nl
type
label
Drug resistance and virologic ...... previously untreated patients.
@en
Drug resistance and virologic ...... previously untreated patients.
@nl
prefLabel
Drug resistance and virologic ...... previously untreated patients.
@en
Drug resistance and virologic ...... previously untreated patients.
@nl
P2093
P1433
P1476
Drug resistance and virologic ...... previously untreated patients
@en
P2093
D L Shugarts
D R Kuritzkes
M A Fallon
M Bakhtiari
S L Benoit
P304
P356
10.1097/00002030-199610090-00007
P407
P577
1996-08-01T00:00:00Z